Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
House dust mite (HDM) avoidance and treatment of severe childhood asthma Source: Eur Respir J 2003; 22: Suppl. 45, 314s Year: 2003
Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
The reduction of the house dust mite as a prevention component in a treatment of the asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 335s Year: 2002
Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
The effect of montelukast during allergen sensitization period in house dust mite mouse model Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017
The association of adult bronchial responsiveness with IgE sensitisation and exposure to cat and house dust mite allergen Source: Eur Respir J 2006; 28: Suppl. 50, 145s Year: 2006
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Phospho-STAT-6 levels in nasal scrapings of asthmatic patients increases following nasal challenge with grass but not house dust mite allergen Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Association between house dust mites (HDM) level in homes of atopic children and interleukine-4 and IgE in expired air condensate(EAC) Source: Eur Respir J 2002; 20: Suppl. 38, 536s Year: 2002
House dust mite allergen exposure is associated with sensitisation and asthma in New Zealand infants Source: Eur Respir J 2002; 20: Suppl. 38, 117s Year: 2002
Sublingual tablets of house dust mite allergen extracts: Results of a phase I study in adults with mite-associated allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013